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Ivan Degrieck, MD, FETCS,a Aalst, BelgiumFIGURE 1. Preoperative echocardiogram demonstrating a status-post
mitral valve repair with severe mitral valve regurgitation. TEE, Transeso-
phageal echocardiogram.Percutaneous valve therapy is an emerging therapy for
aortic valve replacement in patients at high surgical risk.1
Favorable results have cautiously extended indications to
high-risk patients with failing bioprostheses.2
Despite proven durability of mitral valve repair, some pa-
tients may require a reoperation and may represent a chal-
lenging surgical risk. The concept of ‘‘valve in ring’’
could be a solution for such patients, but this has, to our
knowledge, been reported only in an experimental setting.3
We recently encountered a patient with failed mitral valve
repair in whom a ‘‘valve in ring’’ procedure was performed.
CLINICAL SUMMARY
An 85-year-old cachectic female patient (1 m 59 cm,
37 kg) came to the emergency department in pulmonary
edema (functional class IV). Her medical history included
rheumatoid arthritis and colorectal cancer that was resected
in 1990. She subsequently underwent chemotherapy and ra-
diotherapy and remained oncologically free of cancer ever
since.
In 2007 she underwent thoracoscopic mitral valve repair
for grade III central mitral valve regurgitation. A 28-mm
Physio I annuloplasty ring (EdwardsLifesciences, Irvine, Ca-
lif) was implanted. The left ventricular ejection fraction at
that time was 50%. Postoperative recovery was uneventful.
Current cardiac investigations revealed grade III–IV mi-
tral valve regurgitation (Figure 1) and a left ventricular ejec-
tion fraction of 20%. No other cardiac abnormalities were
diagnosed.
Given the poor general condition of this patient and her
high logistic EuroSCORE (82.3%), she was judged to be
at too high a risk for reoperation via either sternotomy or
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The procedure was performed on June 17, 2010. A small
left anterolateral thoracotomy was performed. The patient
was given 5000 units of heparin and the activated clotting
time was kept above 180 seconds. A bipolar pacemaker
wire was placed on the left ventricle.
The apex was punctured and a Terumo stiff wire
(Terumo Europe, Leuven, Belgium) was introduced into
the left ventricle. A head-hunter catheter (Cook, Inc,
Bloomington, Ind) was used to catheterize the left atrium.
The Terumo wire was then exchanged for a Amplatz Super
Stiff straight tip guidewire (Boston Scientific, Natick,
Mass), which was positioned in the upper left pulmonary
vein.
No balloon dilatation of the mitral valve was performed.
A 26-mm Sapien aortic valve (Edwards Lifesciences) was
inversely mounted on the delivery balloon and introduced
through the mitral ring. The valve was positioned so that
the annuloplasty ring would be in between the inflow and
outflow of the Sapien valve.
Under rapid ventricular pacing, the Sapien valve was
positioned into the Physio ring. During insufflation, the
shape of the Physio ring changed from oval to almost per-
fectly circular (Figure 2). A very small paravalvular intra-
annular leak was noted and treated conservatively.diovascular Surgery c Volume 141, Number 5 1317
FIGURE 2. Postprocedure fluoroscopic views showing the ‘‘valve in ring.’’ Notice the almost circular shape of the mitral ring on the lateral view.
Brief Technique ReportsThe postoperative course was relatively uneventful. Am-
bulation was somewhat delayed because of the poor preop-
erative condition. Hospital length of stay was 12 days.
DISCUSSION
With the aging of the population, an increasing number of
patients may come for primary intervention or reoperation.
Consequently, the operative risk will markedly increase be-
cause of advanced age or comorbidities. Despite our favor-
able experience in cardiac mitral valve reoperation using
the Port-Access method,4 even in patients with an exces-
sively high EuroSCORE, the operative risk in this patient
was judged too high.
Our biggest concern was the oval shape of the Physio I
ring versus the circular shape of the Sapien valve. However,
experimental work of the Leipzig group3 had demonstrated
the adaptability of the Physio I ring into a circular form at
balloon insufflation. Also, their work had demonstrated
that a 26-mm Sapien valve would fit into a 28-mm Physio
I ring. Our clinical experience confirmed their experimental
findings.
We believe that the ‘‘valve in ring’’ concept will play an
increasing role in the future in reducing the reoperative1318 The Journal of Thoracic and Cardiovascular Surmortality in patients with failed mitral valve repair. How-
ever, patients with implanted rings larger than 28 mm re-
main a matter of concern. On the basis of experimental
work,3 a larger size percutaneous valve would be needed
in such a situation. We therefore hope that larger percutane-
ous valves will be developed to cope with these challenging
situations.
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